Abiopharma

🔍 ANDRESKI PETER M (Executive)

Company: VISA INC. (V)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 4,170 shares of Class A Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,952.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,714 shares of Class A Common Stock at $364.15 per share (Direct)
  Date: 2026-08-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 10,238.00 | transaction_form_type: 4
• Sold 4,170 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Acquired 5,492 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,492.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest in two installments: 50% on the second anniversary of the grant date and 50% on the third anniversary of the grant date, subject to earlier vesting in full in limited circumstances as specified in the award agreement. The award was granted on August 15, 2023.
• F2: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest in one installment: 100% on the third anniversary of the grant date, subject to earlier vesting in full in limited circumstances as specified in the award agreement. The award was granted on August 15, 2026.